STRI logo images

STRI logo images

Stem Cell Treatment & Research Institution

History:

STRI has been all about turning the future into a reality that bears greater meaning for all mankind. Now we stand at a critical turning point where our simple but meaningful discovery is turning into a tangible discovery; thanks to the many collaborators who are looking forward together with us.

content img

2021-2023

  • 2023.

    - STRI published the research article :
    1. Recovery from BEll's palsy after treatment using uncultured umbilical cord-derived mesenchymal stem cells: A case report". World J Clin Cases. 2023 April 26;11(12):2817-2824. DOI : 10.12998/wjcc.v11.i12.2817

  • 2022.

    - Approval Cell Facility Lisencse from Japan FDA

    - STRI published the research article :
    1. Treatment of syringomyelia using uncultured umbilical cord mesenchymal stem cells: A case report and review of literature

    - World J Stem Cells. 2022 April 26; 14(4): 303-309. DOI: 10.4252/wjsc.v14.i4.303

  • 2021.

    - Approval Cell Facility License from KFDA
    - Approval Human Cell-Related Operation License from KFDA
    - STRI published the research articles :
    1. "Treatment of acute ischemic stroke by minimally manipulated umbilical cord-derived mesenchymal stem cells transplantation: A case report". World J Stem Cells. 2021 Aug 26;13(8):1151-1159. doi: 10.4252/wjsc.v13.i8.1151.

    2. "Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: A case report". World J Clin Cases. 2021 Aug 16;9(23):6798-6803. doi: 10.12998/wjcc.v9.i23.6798.

    3. "Alopecia treatment using minimally manipulated human umbilical cord-derived mesenchymal stem cells: Three case reports and review of literature". World J Clin Cases 2021; 9(15): 3741-3751 [PMID: 34046478 DOI: 10.12998/wjcc.v9.i15.3741].

content img

2018-2020

  • 2020.

    - STRI has applied 334 patents related to nEPS over 156 countries and 283 patents are registered in the US, the EU, Israel, Singapore, Australia, Japan, Russia, China, etc.

  • 2018.

    - Registered 280 newly Elicited pluripotent stem cells without side effects (nEPS) patents in Korea,US, EU, Australia, Singapore, Japan and Isreal etc.
    - Research collaboration with University of Michigan

content img

1999-2017

  • 2016.

    - Pre-clinical trialusing hepatocyte-like differentiated cells from nEPS (from Korea) with Seoul National Univ. Bundang Hospital

  • 2015.

    - Registered newly Elicited Pluripotent Stem Cells without side effects (nEPS) 16 registered and 94 related patents applied in 146 countries

  • 2014.

    - Differentiated nEPS cells into six different organ cells – pancreatic beta cells, neurocytes, hepatocytes, adipocytes, osteoblasts and chondrocytes

  • 2013.

    - Discovered the world’s first newly Elicited Pluripotent Stem Cells without side effects (nEPS)

  • 2007.

    - Research arm expanded into the Stem Cell Treatment & Research Institute

  • 2000.

    - STRI Fundamental Sciences Department launched with 3 sub-divisions

    - STRI Life Sciences Research Center receives Korea Industrial Technology Association (KOITA) certification

    - STRI Agricultural Life Sciences Research Center completed Plant Products Manufacturing Plant

  • 1999.

    - Renamed STRI Stem Cell Research Institute

content img

1989-1998

  • 1997.

    - STC Nara opens manufacturing plant in Cheonan

  • 1995.

    - Established STC Agricultural Life Sciences Research Center

  • 1989.

    - Established STRI Life Sciences Research Center (with the core values of Soul, Treatment & Cell to contribute to mankind by developing stem cell based therapy with a righteous mind.)